EpiAxis Therapeutics has expanded its clinical trial program to include two additional recruitment centres for its Phase 1b metastatic breast cancer program. The centres open for patient recruitment are the Southern Medical Day Care Centre in Wollongong and at the...
EpiAxis Phase 1 FPI News Release
There is currently no therapy to fight recurrent, metastatic breast cancer, which is the major source of death in women with breast cancer. Furthermore, current first-line treatments have extensive side-effects.We are determined to fix that.
Professor Sudha Rao
Founder at EpiAxis Therapeutics